Tribulus Terrestris Versus Placebo In The Treatment Of Erectile Dysfunction And Lower Urinary Tract Symptoms In Patients With Late-onset Hypogonadism: A Placebo-controlled Study

Effect Increase
Values PSA-t increased from 1.38 to 1.66 in the intervention group whereas no change was seen in the placebo group. Statistical significance pertains to within-group difference for intervention.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 70
Sex Male
Age Range 30-44, 45-64, 65+
Notes for this study:
70 men with erectile dysfunction and partial androgen deficiency took either 750 mg/d of Tribulus (divided into 3 equal doses) or placebo for 3 months. Participants in the Tribulus group saw a significant increase in aspartate transaminase, total testosterone, and erectile function relative to baseline. There was a significant increase in prostate-specific antigen and no significant change in alanine transaminase or the international prostate symptom score. There were no between-group comparisons, however, the placebo group saw no significant changes in any parameter.